Systematic review and Meta-analysis of efficacy and safety of Shufeng Jiedu Capsules in treatment of influenza / 中国中药杂志

This study aims to systematically review the efficacy and safety of Shufeng Jiedu Capsules in the treatment of influenza. The randomized controlled trial(RCT) of Shufeng Jiedu Capsules alone or in combination with conventional western medicine for treating influenza were retrieved from PubMed, EMbase, Cochrane Library, Web of Science, SinoMed, CNKI, VIP, Wanfang, and ClinicalTrails.gov. The data analysis was performed in RevMan 5.4.1. The Cochrane risk of bias assessment tool was used to evaluate the quality of the involved RCT, and GRADEpro GDT to assess the quality of the evidence. A total of 11 RCTs involving 1 836 patients were included in this study. Compared with conventional western medicine, Shufeng Jiedu Capsules/Shufeng Jiedu Capsules + conventional western medicine improved the response rate(RR=1.09, 95%CI[1.03, 1.15], P=0.002), shortened the time to relief of cough, and increased the 3-day sore throat relief rate, whereas there was no significant difference in the time to fever abatement, the time to relief of sore throat, 3-day cough relief rate, or 3-day runny nose relief rate. Subgroup-analysis showed that Shufeng Jiedu Capsules + conventional western medicine improved the response rate(RR=1.11, 95%CI[1.08, 1.15], P<0.000 01), shortened the time to relief of cough, and increased the 3-day relief rate of symptoms(cough, sore throat, and runny nose) compared with conventional western medicine alone, while there was no significant difference in the time to fever abatement or the time to relief of sore throat. Shufeng Jiedu Capsules alone could not improve the response rate(RR=0.97, 95%CI[0.93, 1.02], P=0.19). In addition, Shufeng Jiedu Capsules/Shufeng Jiedu Capsules + conventional western medicine vs conventional western medicine were no significant difference in adverse reactions(RR=0.98, 95%CI[0.57, 1.69], P=0.95). The available evidence suggests that Shufeng Jiedu Capsules is effective and safe in the treatment of influenza, and the combination of Shufeng Jiedu Capsules with conventional western medicine can accelerate the relief of symptoms. However, since the number and quality of the included studies were low, the above findings remained to be further verified by multicenter RCT with large sample sizes.

Overview of systematic reviews of Shufeng Jiedu Capsules / 中国中药杂志

At present, there have been many clinical trials and systematic reviews/Meta-analysis proving the good clinical efficacy of Shufeng Jiedu Capsules in the treatment of respiratory diseases, while comprehensive discussion is still required. This article overviews and analyzes the systematic reviews/Meta-analysis of Shufeng Jiedu Capsules to provide evidence support for clinical practice. The systematic reviews/Meta-analysis of Shufeng Jiedu Capsules were searched from CBM, Wanfang, CNKI, VIP, PubMed, EMbase and Cochrane Library. The AMSTAR 2 scale and GRADE system were respectively employed for the evaluation of methodological quality and the grading of evidence quality. Finally, 8 systematic reviews/Meta-analysis published during 2018-2021 were included for analysis. The diseases involved include acute exacerbation of chronic obstructive pulmonary disease, community-acquired pneumonia, acute tonsillitis, acute exacerbation of chronic bronchitis and acute upper respiratory tract infection. The number of included RCTs studies ranged from 8 to 25. The results showed that Shufeng Jiedu Capsules combined with western medicine routine had better therapeutic effect than the latter alone in the treatment of the above five diseases. The reported adverse reactions caused by Shufeng Jiedu Capsules were mainly gastrointestinal discomforts such as mild nausea, diarrhoea and vomiting, with low incidence and mild symptoms, which can be relieved by drug withdrawal. The methodological quality of the included studies was extremely low, and the outcome indicators were mainly of low and very low grades. The efficacy and safety of Shufeng Jiedu Capsules in the clinical treatment of diseases still need to be verified based on more high-quality studies. The relevant clinical research and systematic review/Meta-analysis should pay more attention to methodological quality and reporting standards and strengthen the scientificity of research.

Curative Effect of Shufeng Jiedu Capsules Combined with Conventional Treatment on Upper Airway Cough Syndrome / 中国药师

Objective:To observe the clinical effect of Shufeng Jiedu capsules combined with the conventional treatment on upper airway cough syndrome(UACS). Methods:Totally 55 patients with UACS and basic nasal or sinus diseases were randomly divided into two groups:the treatment group (n = 28) and the control group (n = 27). The treatment group was treated with Shufeng Jiedu capsules combined with the regimen for the control group,40 mg·kg-1,3 times a day, and the regimen for the control group was as follows:loratadine tablets, 10 mg,qd, budesonide nasal spray hormone 128 μg, bid, roxithromycin dispersible tablets,0.15 g,qd. The treatment course was 4 weeks. The changes of symptom scores were observed and the adverse reactions were recorded to compare the efficacy between the groups. Results:The total effective rate of the treatment group was 85.71%, which was significantly higher than that of the control group(75.37%,P <0.05). The cough and nasal symptoms were notably improved in the two groups after the treatment(P < 0.05),and all the symptom scores in the treatment group were better than those in the control group (P < 0.05). Conclusion:Shufeng Jiedu capsules combined with the conventional treatment can improve the efficacy in the treatment of UACS.

Anti-inflammatory mechanism of Shufeng Jiedu Capsules in rat pneumonia model / 中草药

Objective To explore the anti-inflammatory mechanism of Shufeng Jiedu Capsules (SJC). Methods The Streptococcus pneumoniae (SP)-induced pneumonia model of rats was used to study the anti-inflammation of SJC. The factors related to inflammatory response from the blood plasma such as leukocyte count and its classification, complement C3, bradykinin (BK), monocyte chemotactic protein (MCP-1), NF-κB, COX-1, COX-2, and bacterial count were measured after the administration of SJC. Results SJC significantly decreased the bacterial count in peripheral blood and BALF, and leukocyte in peripheral blood; It also significantly reduced the levels of NF-κB, MCP-1, BK, and COX-2 in serum. Conclusion SJC has significant sterilization and anti-inflammation effects, which shows significantly therapeutic effect on pneumonia model rats by reducing the levels of NF-κB, MCP-1, BK, and COX-2.